## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($93.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Boston Scientific gets European nod for Farapoint catheter**
- Source: MassDevice | 20251204T162135 | Bullish | Relevance: 100%
- Boston Scientific recently received CE mark for its Farapoint pulsed field ablation (PFA) catheter, allowing it to be marketed in Europe for treating right atrial flutter (AFL). This expands the indications for its Farapulse PFA platform, which was initially approved for AFib. The company aims to become a top player in the electrophysiology space, leveraging the Farapoint catheter's demonstrated efficacy and safety in preventing AFL recurrence.

**2. Quantbot Technologies LP Grows Holdings in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251204T000801 | Bullish | Relevance: 100%
- Quantbot Technologies LP increased its stake in Boston Scientific Corporation (NYSE:BSX) by 17.5% in the second quarter, now owning 163,745 shares valued at $17.59 million, making it their 25th largest holding. Wall Street analysts maintain a "Buy" consensus rating for BSX with an average price target of $123.77, following strong Q3 earnings where the company beat estimates and provided positive FY2025 guidance. However, company insiders have sold approximately 125,782 shares worth $12.47 million in the past 90 days.

**3. Boston Scientific Stock (BSX) on December 3, 2025: Insider Sales, EU Device Win and Strong 2026 Price Targets**
- Source: ts2.tech | 20251203T233558 | Bullish | Relevance: 100%
- This article provides a detailed snapshot of Boston Scientific (BSX) stock on December 3, 2025, highlighting recent insider sales, a significant EU device approval for its Farapoint pulsed field ablation catheter, and strong analyst price targets for 2026. It also recaps the company's Q3 2025 earnings, growth drivers, valuation, and risks, indicating a premium-valued medtech leader with bullish prospects tempered by insider selling and high valuation.

**4. Boston Scientific executive exercises options, sells 17,313 shares | BSX SEC Filing - Form 4**
- Source: Stock Titan | 20251203T101050 | Neutral | Relevance: 100%
- An executive at Boston Scientific (BSX) exercised stock options for 17,313 shares at various prices and subsequently sold all 17,313 shares on the open market for a weighted average price of $101.5531 per share. These transactions, executed on December 1, 2025, were conducted under a pre-established Rule 10b5-1 trading plan. Following these sales, the executive directly holds 23,600 shares and indirectly holds 13,354 shares through a 401(k) plan.

**5. Boston Scientific (BSX): Evaluating Valuation as Growth Prospects Draw Fresh Investor Interest**
- Source: Simply Wall Street | 20251202T230728 | Bullish | Relevance: 100%
- Boston Scientific (BSX) is gaining investor attention due to strong demand for its less-invasive cardiac and chronic-pain solutions, and its leadership in heart rhythm management. The company has seen significant share price appreciation and total shareholder returns, prompting questions about its current valuation. While one narrative suggests the stock is undervalued with a fair value of $126.48, another perspective highlights an elevated price-to-earnings ratio compared to the industry average, signaling potential risk.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $132 | $132 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $142.4B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 28.2 |
| Current P/E | 32.2 |
| YoY Growth | 14.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.7% to -3.4% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.4pp (needs >3.0% for momentum thesis). Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 43. OFD pattern: -STN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.40% (CS: 16) | Weak |
| RSI_14 | 42.9 | Neutral |
| MACD Histogram | -0.22 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 0.985x | Below |
| vs SMA200 | 0.963x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $97.72
- **Stop Loss:** $93.56 (4.3% risk)
- **Target:** $101.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 120
- **Position Value:** $11,726.40
- **Portfolio %:** 11.73%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*